GSA Capital Partners LLP bought a new stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 413,545 shares of the company’s stock, valued at approximately $856,000.
Several other large investors have also modified their holdings of ALXO. Invesco Ltd. purchased a new stake in shares of ALX Oncology in the 1st quarter worth approximately $46,000. AQR Capital Management LLC increased its holdings in ALX Oncology by 183.6% during the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after buying an additional 77,065 shares during the period. Acadian Asset Management LLC increased its holdings in ALX Oncology by 16.8% during the first quarter. Acadian Asset Management LLC now owns 1,296,331 shares of the company’s stock valued at $806,000 after buying an additional 186,883 shares during the period. Jane Street Group LLC bought a new position in ALX Oncology in the second quarter worth approximately $84,000. Finally, Bridgeway Capital Management LLC bought a new position in ALX Oncology in the third quarter worth approximately $66,000. Institutional investors own 97.97% of the company’s stock.
Analyst Ratings Changes
A number of analysts have weighed in on the company. Wall Street Zen raised ALX Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings downgraded ALX Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 5th. Five research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $4.60.
ALX Oncology Price Performance
Shares of ALXO opened at $2.08 on Wednesday. The company has a market cap of $287.62 million, a price-to-earnings ratio of -1.84 and a beta of 0.42. ALX Oncology Holdings Inc. has a twelve month low of $0.80 and a twelve month high of $2.66. The company has a quick ratio of 9.71, a current ratio of 9.71 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average of $1.93 and a two-hundred day moving average of $1.96.
ALX Oncology (NASDAQ:ALXO – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. As a group, analysts predict that ALX Oncology Holdings Inc. will post -0.61 earnings per share for the current fiscal year.
About ALX Oncology
ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.
The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.
See Also
- Five stocks we like better than ALX Oncology
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Want to see what other hedge funds are holding ALXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report).
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
